No Correlation Between Estrogen Metabolites, Colorectal Cancer Risk
the Cancer Therapy Advisor take:
Estrogen metabolites (EM), including estrone and estradiol, have no relationship to colorectal cancer (CRC) in postmenopausal women, according to a study published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in the study included 15,595 women between 55 to 80 years who donated blood between 1992 and 1993 for cancer through December 2004. A panel of 15 EM (eg, estrone and estradiol) was measured from 187 cases of CRC.
Results showed no significant associations between estrone (HRQ4 v Q1 = 1.15; 95% CI: 0.69, 1.93; Ptrend =0.54), estradiol (HRQ4 v Q1= 0.98; 95% CI: 0.58, 1.64; Ptrend >0.99) or total EM (the sum of all EM; HRQ4 v Q1=1.35; 95% CI: 0.81, 2.24; Ptrend=0.33) and CRC risk.
Specifically, the metabolites with a 2-, 4-, or 16-pathway had no related risk. However, a borderline trend was observed with high levels of 17-epiestriol.
The study suggests that future research focus on understanding how exogenous estrogen may be associated with prevention of CRC.
Estrogen metabolites, including estrone and estradiol, have no relationship to colorectal cancer in postmenopausal women.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- FDA Grants Breakthrough Therapy Designation to Adjuvant Dabrafenib Plus Trametinib for Melanoma
- Long-term Eltrombopag Improves Outcomes in Chronic Immune Thrombocytopenia
- Phase 1 Trial of Guadecitabine With Vaccine and Cyclophosphamide for Metastatic Colorectal Cancer
- Success of Adoptive Cell Therapy in ALL Could Be Applied to Myeloma
- Curative-intent Surgery for Cancer Increases Risk of New Persistent Opioid-use